Teva Pharmaceutical Industries is reported to account for 22 percent of generic prescriptions written in the US. The company targets biologics that are protein-based therapies worth around $60 billion a year that treat diseases such as cancer. This sector has yet to attract other generic companies. CEO Shlomo Yanai disagrees with executives who allege that generic drugs cut into exclusivity periods and profits therefore impeding their ability to invent new products.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지